Methyl selenocysteine: Single-dose pharmacokinetics in men

James R. Marshall*, Clement Ip, Karen Romano, Gerald Fetterly, Marwan Fakih, Borko Jovanovic, Marjorie Perloff, James Crowell, Warren Davis, Renee French-Christy, Alexander Dew, Margerie Coomes, Raymond Bergan

*Corresponding author for this work

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

The recently published report of the SELECT evaluation of selenium and vitamin E provided strong evidence that selenium 200 μg per day in the form of selenomethionine does not protect selenium-replete men against prostate or any other cancer. This seems to refute the result of the much smaller Nutritional Prevention of Cancer (NPC) trial of selenium. Because SELECT did not test the NPC agent, it is possible that the difference between the two trials stems partly from the use of different agents: selenomethionine in SELECT, and selenized yeast in the NPC trial. One of the organic selenium forms suspected of having strong chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine. This study characterizes the single-dose pharmacokinetics of methyl selenocysteine.

Original languageEnglish (US)
Pages (from-to)1938-1944
Number of pages7
JournalCancer Prevention Research
Volume4
Issue number11
DOIs
StatePublished - Nov 1 2011

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Marshall, J. R., Ip, C., Romano, K., Fetterly, G., Fakih, M., Jovanovic, B., Perloff, M., Crowell, J., Davis, W., French-Christy, R., Dew, A., Coomes, M., & Bergan, R. (2011). Methyl selenocysteine: Single-dose pharmacokinetics in men. Cancer Prevention Research, 4(11), 1938-1944. https://doi.org/10.1158/1940-6207.CAPR-10-0259